Gynäkologische Endokrinologie

, Volume 15, Issue 2, pp 116–120 | Cite as

Adipositas – polyzystisches Ovarialsyndrom – Krebs

Leitthema
  • 95 Downloads

Zusammenfassung

Adipositas und das polyzystische Ovarialsyndrom („polycystic ovary syndrome“ [PCOS]) haben eine ansteigende Inzidenz in der Bevölkerung. Das PCOS ist ein multifaktorielles Geschehen, dessen Pathophysiologie letztlich nicht geklärt ist. Bezüglich der Pathogenese des PCOS werden verschiedene Hypothesen diskutiert, die ovarielle, genetische und zentrale Ursachen sowie die Insulinresistenz einbeziehen. Adipositas findet sich häufig vergesellschaftet mit dem PCOS; Gewichtszunahme steht in einem kausalen Zusammenhang mit PCOS-typischen Erscheinungsbildern wie Oligomenorrhö und Hyperandrogenismus. Bei Frauen gibt es ein pathomorphes Kontinuum aus Adipositas, PCOS und metabolischem Syndrom. Die Fettleibigkeit führt zu Störungen der reproduktiven Organe und ist ein wichtiger Fertilitätsfaktor. Ernst zu nehmen ist die Fettleibigkeit als Risikofaktor von metabolischen und Herz-Kreislauf-Erkrankungen. Mehr noch kann die Fettleibigkeit pathophysiologisch der Entstehung maligner Erkrankungen zugrunde liegen.

Schlüsselwörter

Metabolisches Syndrom Anti-Müller-Hormon Mammakarzinom Endometriumkarzinom Ovarialkarzinom 

Obesity, polycystic ovary syndrome, cancer

Abstract

The incidence of obesity and polycystic ovary syndrome (PCOS) in the population is constantly increasing. The PCOS is a multifactorial event for which the pathophysiology has not yet been clarified. Various hypotheses are discussed with respect to the pathogenesis of PCOS, which include ovarian, genetic and central causes as well as insulin resistance. Obesity often occurs together with PCOS and increased body weight have a causal connection with symptoms typical for PCOS, such as oligomenorrhea and hyperandrogenism. there is a pathomorphic continuum consisting of obesity, PCOS and metabolic syndrome. Obesity leads to disorders of the reproductive organs and is an important factor in fertility. Obesity must be taken seriously as a risk factor for metabolic and cardiovascular diseases. Additionally, obesity can be the pathophysiological basis for the risk of malignant diseases.

Keywords

Syndrome, metabolic Anti-Mullerian hormone Breast cancer Endometrial cancer Ovarian cancer 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

J. Weiss und W. Küpker geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Achard C, Thiers J (1921) Le virilisme pilaire et son association a I’insuffisance glucolytique (diabetes des femmes barb). Bull Acad Natl Med 86:51–64Google Scholar
  2. 2.
    Barry JA, Aziza MM, Hardiman PJ (2014) Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 20:748–758CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Cassar S, Misso ML, Hopkins WG, Shaw CS, Teede HJ, Stepto NK (2016) Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod 31(11):2619–2631CrossRefPubMedGoogle Scholar
  4. 4.
    Catalan V, Gomez-Ambrosi J, Rodriguez A, Salvador J, Fruhbeck G (2009) Adipokines in the treatment of diabetes mellitus and obesity. Expert Opin Pharmacother 10:239–254CrossRefPubMedGoogle Scholar
  5. 5.
    Cimino I, Casoni F, Liu X, Messina A, Parkash J, Jamin SP, Catteau-Jonard S, Collier F, Baroncini M, Dewailly D, Pigny P, Prescott M, Campbell R, Herbison AE, Prevot V, Giacobini P (2016) Novel role for anti-Müllerian hormone in the regulation of GnRH neuron excitability and hormone secretion. Nat Commun 12(7):10055. doi: 10.1038/ncomms10055 CrossRefGoogle Scholar
  6. 6.
    Comninos AN, Jayasena CN, Dhillo WS (2014) The relationship between gut and adipose hormones, and reproduction. Hum Reprod Update 20:153–174CrossRefPubMedGoogle Scholar
  7. 7.
    Diamanti-Kandarakis E, Dunaif A (2012) Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 33:981–1030CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Dizdar O, Alyamac E (2004) Obesity: an endocrine tumor? Med Hypotheses 63:790–792CrossRefPubMedGoogle Scholar
  9. 9.
    Dunaif A, Finegood DT (1996) Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 81(3):942–947PubMedGoogle Scholar
  10. 10.
    Dunaif A, Segal KR, Futterweit W, Dobrjansky A (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38(9):1165–1174CrossRefPubMedGoogle Scholar
  11. 11.
    Franks S, Stark J, Hardy K (2008) Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update 14(4):367–378CrossRefPubMedGoogle Scholar
  12. 12.
    Heard E, Martienssen RA (2014) Transgenerational epigenetic inheritance: myths and mechanisms. Cell 157:95–109CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Jones MR, Goodarzi MO (2016) Genetic determinants of polycystic ovary syndrome: progress and future directions. Fertil Steril 106(1):25–32CrossRefPubMedGoogle Scholar
  14. 14.
    Franks S, Stark J, Hardy K (2008) Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update 14(4):367–378CrossRefPubMedGoogle Scholar
  15. 15.
    McAllister JM, Modi B, Miller BA et al (2014) Overexpression of a DENND1A isoform produces a polycystic ovary syndrome theca phenotype. Proc Natl Acad Sci USA 111:E1519–E1527CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Nelson VL, Qin KN, Rosenfield RL et al (2001) The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 86:5925–5933CrossRefPubMedGoogle Scholar
  17. 17.
    Pierpoint T, McKeigue PM, Isaacs AJ et al (1998) Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 51:581–586CrossRefPubMedGoogle Scholar
  18. 18.
    Pillay OC, TeFong LF, Crow JC et al (2006) The association between polycystic ovaries and endometrial cancer. Hum Reprod 21:924–929CrossRefPubMedGoogle Scholar
  19. 19.
    Rosenfield RL, Barnes RB, Cara JF, Lucky AW (1990) Dysregulation of cytochrome P450c 17 alpha as the cause of polycystic ovarian syndrome. Fertil Steril 53(5):785–791CrossRefPubMedGoogle Scholar
  20. 20.
    Stein IF, Leventhal ML (1935) Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 29:181–191CrossRefGoogle Scholar
  21. 21.
    Valtcheva N, Lang FM, Noske A et al (2017) Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing – a case report. BMC Cancer 17:66–75CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Vincent HK, Taylor AG (2006) Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int J Obes (Lond) 30:400–418CrossRefGoogle Scholar
  23. 23.
    Weichenhan D, Plass C (2013) The evolving epigenome. Hum Mol Genet 22:R1–R6CrossRefPubMedGoogle Scholar
  24. 24.
    Yen SS, Vela P, Rankin J (1970) Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease. J Clin Endocrinol Metab 30(4):435–442 (Apr)CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH 2017

Authors and Affiliations

  1. 1.Abteilung für Endokrinologie und ReproduktionsmedizinKantonsspital LuzernLuzernSchweiz
  2. 2.Zentrum für Minimalinvasive Gynäkologie, Endometriose und Reproduktionsmedizin, Frauenklinik Baden-Baden – BühlKlinikum MittelbadenBühlDeutschland

Personalised recommendations